GSK agreed to acquire Nuvalent for $10.6 billion in cash, positioning the deal to add two near-commercial non-small cell lung cancer (NSCLC) programs to its pipeline. The acquisition brings zidesamtinib (ROS1 inhibitor) and neladalkib (ALK inhibitor), both under FDA review with potential 2026 approval timelines. The transaction is designed to complement GSK’s broader lung cancer strategy, including Ris-Rez, its B7-H3 targeted antibody-drug conjugate program in Phase III. GSK also receives NVL-330, a HER2 inhibitor in Phase I studies for HER2-altered NSCLC, plus a preclinical Nuvalent portfolio. GSK structured the bid at $124 per share for Nuvalent, reflecting a premium to recent trading levels. Management framed the two reviewed assets as potential best-in-class options, with target decision dates of Sept. 18, 2026 for zidesamtinib and Nov. 27, 2026 for neladalkib, subject to regulatory outcomes.